Tirzepatide

Estimated Market Price

$164.99 – $179.99

Based on verified supplier pricing for research-grade compounds

Dual GIP/GLP-1 receptor agonist — the next generation in weight management and metabolic health. Premium purity, independently verified.

How it works

Activates two gut hormone receptors (GIP and GLP-1) at once, suppressing appetite and improving blood sugar control more powerfully than single-receptor drugs like semaglutide.

Performance

Weight Management

bestseller trending

What to Expect

Week 1–4 Appetite suppression emerges; GI side effects peak then ease. Strong appetite drop; may feel nauseous first few days.

Week 5–8 Dose escalation continues; 4–6% weight loss typical. Pants getting loose; sugar cravings basically gone.

Week 9–12 Dual-receptor effects fully active; energy and cravings improve. Significant visible change; energy levels much higher.

Week 13–16 Major body recomposition visible; metabolic panels normalize. Major transformation visible; feel like a different person.

Week 17+ Maintenance dosing; sustained weight management continues. Maintaining easily; appetite naturally smaller.

Verified Suppliers

For research purposes only. These suppliers have been independently verified by PepSpace. We do not process sales directly.

PepSpace is not affiliated with any listed supplier

LarnaLabs Verified Supplier · larnalabs.com

PepSpace Verified Supplier · pepspace.io

BioSynth Verified Custom Batch Supplier · biosynth.com

Peptide Sciences Unavailable · peptidesciences.com

Protocol & Dosage

Typical Dosage 2.5 mg/week titrating to 10–15 mg/week SC

Administration Subcutaneous injection

Schedule Once weekly, same day each week

Protocol Duration 12–16+ weeks (ongoing for weight management)

Half-Life ~5 days

Side Effects & Safety

Tolerability Profile Moderate

Notable side effects likely; manageable with proper awareness

Common Side Effects

Nausea~31%
Diarrhea~21%
Decreased appetite~20%
Vomiting~12%
Dyspepsia~9%
Constipation~7%
Abdominal pain~6%
Injection site reaction~3%

Less Common

Hair loss~5%
Gallstones or gallbladder disease~2%
Increased heart rate~1%
Flatulence~1%
GERD / acid reflux~1%

Rare / Serious

Pancreatitis<0.3%
Acute kidney injury (dehydration)rare
Hypoglycemia (with insulin use)rare

Discontinue If

Severe abdominal pain radiating to back (pancreatitis)
Persistent vomiting or inability to hydrate
Neck lump, hoarseness, or swallowing difficulty (thyroid)
Signs of severe allergic reaction

Contraindications

Personal or family history of medullary thyroid carcinoma
Multiple endocrine neoplasia type 2 (MEN2)
History of pancreatitis
Pregnancy or breastfeeding

Data note: Studied in SURPASS/SURMOUNT trials (12,000+ participants). GI side effects peak during dose escalation and typically resolve.

Always consult a qualified healthcare professional before use. This information is for research reference only and does not constitute medical advice.

Ask about Tirzepatide

How to Apply

Gather

Peptide vial, BAC water, alcohol swabs, insulin syringe

Sanitize

Wipe tops of both vials with alcohol swabs

Draw

Pull 1–2 mL of BAC water into syringe

Add Water

Release water slowly along vial wall, not directly on powder

Swirl

Roll between palms until dissolved. Never shake.

Store

Refrigerate 2–8°C, use within 30 days

Frequently Asked Questions

Yes. Bacteriostatic water (BAC water) is required to reconstitute lyophilized (freeze-dried) peptides. It contains 0.9% benzyl alcohol which prevents bacterial growth, keeping your reconstituted peptide safe for multiple uses over up to 30 days.

Unreconstituted: store at -20°C (freezer) for long-term, or 2–8°C (fridge) for short-term. After reconstitution: always refrigerate at 2–8°C and use within 30 days. Keep away from direct sunlight.

Results vary by individual and protocol. In research settings, measurable effects are typically observed within 1–4 weeks depending on the specific peptide, dosage, and application. Consult a qualified professional for guidance.

Verified suppliers typically include a full third-party COA verifying purity (99%+), identity, and sterility. We recommend only sourcing from vendors that provide batch-specific testing data.

We list verified suppliers above that have been independently reviewed for product quality, testing transparency, and shipping reliability. Always verify COA data before sourcing.

Compound Profile

Scientific data & classification for Tirzepatide

Also Known As Mounjaro, Zepbound, LY3298176

Classification Dual GIP/GLP-1 Receptor Agonist · Metabolic

Sequence Modified GIP/GLP-1 dual agonist (39 aa)

Molecular Formula C₂₂₅H₃₄₈N₄₈O₆₈

Molecular Weight 4,813.45 Da

CAS Number 2023788-19-2

Half-Life ~5 days

Origin Synthetic dual incretin mimetic

Administration Subcutaneous injection

Status FDA Approved - diabetes (2022), weight management (2023)

Mechanism of Action Activates two gut hormone receptors (GIP and GLP-1) at once, suppressing appetite and improving blood sugar control more powerfully than single-receptor drugs like semaglutide.

Research Overview Tirzepatide, developed by Eli Lilly and Company under the code name LY3298176, emerged from a novel therapeutic concept of simultaneous dual incretin receptor agonism and rapidly established itself as the most potent anti-obesity pharmaceutical compound in clinical development. Approved by the FDA in May 2022 for type 2 diabetes (as Mounjaro) and in November 2023 for chronic weight management (as Zepbound), tirzepatide is a synthetic linear peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor with carefully balanced potency at each target. The compound's 39-amino-acid sequence is based on the native GIP peptide backbone, modified with a C20 fatty diacid moiety conjugated via a linker to a lysine residue, providing strong albumin binding and a half-life of approximately 5 days suitable for once-weekly dosing. The SURPASS clinical trial program in type 2 diabetes demonstrated HbA1c reductions of up to 2.58% and body weight reductions of up to 12.9 kg at the highest dose - results that exceeded those of semaglutide in the head-to-head SURPASS-2 trial. The SURMOUNT obesity trial program produced even more striking outcomes, with the 15 mg dose achieving mean weight loss of 22.5% of body weight at 72 weeks in the SURMOUNT-1 trial, representing a transformative advance in pharmacological weight management. The dual mechanism provides complementary metabolic benefits - GLP-1 receptor activation delivers the established effects on insulin secretion, glucagon suppression, and appetite reduction, while GIP receptor activation appears to enhance fat tissue insulin sensitivity, improve lipid metabolism, and potentially contribute to preservation of lean mass during weight loss, though the precise contribution of each receptor pathway remains an active area of research.

Citations

Published findings on Tirzepatide from peer-reviewed journals.